NASDAQ:NCNA - Nasdaq - US67022C2052 - ADR - Currency: USD
NCNA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 566 industry peers in the Biotechnology industry. NCNA has a bad profitability rating. Also its financial health evaluation is rather negative. NCNA is valued expensive and it does not seem to be growing.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -128.58% | ||
ROE | -319.06% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.02 | ||
Debt/FCF | N/A | ||
Altman-Z | -18.49 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.42 | ||
Quick Ratio | 1.42 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
0.59
+0.06 (+11.3%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | N/A | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.45 | ||
P/tB | 0.71 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -128.58% | ||
ROE | -319.06% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.02 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 56.13% | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 1.42 | ||
Quick Ratio | 1.42 | ||
Altman-Z | -18.49 |